X
ITCI

Xponance’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Xponance’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,093
Closed -$1.86M – 1552
2025
Q1 		$1.86M Buy
14,093
+484
+4% +$60.3K 0.02% 535
2024
Q4 		$1.14M Buy
13,609
+628
+5% +$51.6K 0.01% 681
2024
Q3 		$950K Sell
12,981
-348
-3% -$26.2K 0.01% 717
2024
Q2 		$913K Buy
13,329
+7,671
+136% +$532K 0.01% 699
2024
Q1 		$392K Sell
5,658
-18
-0.3% -$1.24K ﹤0.01% 1014
2023
Q4 		$407K Buy
5,676
+163
+3% +$9.38K ﹤0.01% 994
2023
Q3 		$287K Buy
5,513
+31
+0.6% +$1.81K ﹤0.01% 1047
2023
Q2 		$347K Sell
5,482
-172
-3% -$10.7K ﹤0.01% 1009
2023
Q1 		$306K Buy
5,654
+31
+0.6% +$1.5K ﹤0.01% 1040
2022
Q4 		$298K Buy
5,623
+22
+0.4% +$1.1K ﹤0.01% 1038
2022
Q3 		$260K Buy
5,601
+666
+13% +$34.8K 0.01% 1035
2022
Q2 		$282K Buy
4,935
+1,101
+29% +$62.4K 0.01% 1028
2022
Q1 		$235K Buy
+3,834
New +$199K ﹤0.01% 1076

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Xponance's ITCI Position: Q2 2025 in Review

Xponance sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 14,093 shares — an estimated $1.86M sold.

Xponance first reported a position in ITCI in Q1 2022 and held it in 13 quarters. The position peaked at $1.86M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Xponance reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Xponance sold 14,093 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $1.86M.
  • Xponance first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 13 quarters.
  • Xponance's Intra-Cellular Therapies Inc. position peaked at $1.86M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Xponance's 13F filing for Q2 2025, filed 14 Aug 2025.